Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of SJP-0035 0.001% for the Treatment of Patients With Dry Eye Disease (DELTA-1 Study)

Trial Profile

A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of SJP-0035 0.001% for the Treatment of Patients With Dry Eye Disease (DELTA-1 Study)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs Fonadelpar (Primary)
  • Indications Dry eyes
  • Focus Registrational; Therapeutic Use
  • Acronyms DELTA-1 Study
  • Sponsors Senju Pharmaceutical
  • Most Recent Events

    • 21 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 30 May 2018 Planned initiation date changed from 14 May 2018 to 31 Aug 2018.
    • 22 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top